EGFR and lung cancer: Surprisingly, we observed a notable decrease in the colony forming ability of DUSP22-deleted HCC827 lung cancer cells when treated with gefitinib at a concentration of 10 nM (Fig. 2E, F), suggesting that higher EGFR activity in DUSP22-deleted HCC827 lung cancer cells may make them more vulnerable to EGFR TKI treatment.